Rosiglitazone decreases albuminuria in type 2 diabetic patients.

[1]  E. Ravussin,et al.  Role of adiponectin in human skeletal muscle bioenergetics. , 2006, Cell metabolism.

[2]  J. Olefsky,et al.  Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. , 2005, Diabetes.

[3]  L. Bouter,et al.  Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction--the Hoorn Study. , 2004, Kidney international. Supplement.

[4]  R. DeFronzo,et al.  A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. , 2004, Archives of internal medicine.

[5]  Y. Miyazaki,et al.  Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. , 2004, The Journal of clinical endocrinology and metabolism.

[6]  C. Yosefy,et al.  Rosiglitazone Improves, While Glibenclamide Worsens Blood Pressure Control in Treated Hypertensive Diabetic and Dyslipidemic Subjects via Modulation of Insulin Resistance and Sympathetic Activity , 2004, Journal of cardiovascular pharmacology.

[7]  Hong Tang,et al.  Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. , 2004, Diabetes research and clinical practice.

[8]  A. Häkkinen,et al.  Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.

[9]  S. Prabhakar.  Role of nitric oxide in diabetic nephropathy. , 2004, Seminars in nephrology.

[10]  B. Goldstein,et al.  Adiponectin: A novel adipokine linking adipocytes and vascular function. , 2004, The Journal of clinical endocrinology and metabolism.

[11]  R. DeFronzo,et al.  Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. , 2004, The Journal of clinical endocrinology and metabolism.

[12]  L. Groop,et al.  Insulin resistance, hypertension and microalbuminuria in patients with Type 2 (non-insulin-dependent) diabetes mellitus , 1993, Diabetologia.

[13]  Hui Chen,et al.  Adiponectin Stimulates Production of Nitric Oxide in Vascular Endothelial Cells* , 2003, Journal of Biological Chemistry.

[14]  M. Carnethon,et al.  Association between microalbuminuria and the metabolic syndrome: NHANES III. , 2003, American journal of hypertension.

[15]  Y. Hattori,et al.  Globular adiponectin upregulates nitric oxide production in vascular endothelial cells , 2003, Diabetologia.

[16]  H. Siragy,et al.  Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. , 2003, Kidney international.

[17]  Y. Miyazaki,et al.  Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. , 2003, Diabetes.

[18]  Masafumi Koga,et al.  Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. , 2003, Metabolism: clinical and experimental.

[19]  G. Bakris,et al.  Rosiglitazone reduces urinary albumin excretion in type II diabetes , 2003, Journal of Human Hypertension.

[20]  Vincent Lebon,et al.  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. , 2002, Diabetes.

[21]  C. Glass,et al.  Peroxisome Proliferator‐Activated Receptors (PPARs) , 2002 .

[22]  N. Ruderman,et al.  Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. , 2002, Diabetes.

[23]  M. Breyer,et al.  Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. , 2001, Kidney international.

[24]  R. Routh,et al.  Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. , 2000, Kidney international.

[25]  G. Cooney,et al.  Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. , 2000, American journal of physiology. Endocrinology and metabolism.

[26]  M. Fujishima,et al.  Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. , 2000, Biochimica et biophysica acta.

[27]  一色 啓二.  Thiazolidinedione Compounds Ameliorate Glomerular Dysfunction Independent of Their Insulin-Sensitizing Action in Diabetic Rats , 2000 .

[28]  Y. Nakatani,et al.  Effect of Troglitazene on Microalbuminuria in Patients With Incipient Diabetic Nephropathy , 1998, Diabetes Care.

[29]  S. Haffner,et al.  Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. , 1998, Diabetes.

[30]  H. Trachtman,et al.  High glucose inhibits nitric oxide production in cultured rat mesangial cells. , 1997, Journal of the American Society of Nephrology : JASN.

[31]  Y. Tomino,et al.  mRNA Expression of Growth Factors in Glomeruli From Diabetic Rats , 1993, Diabetes.

[32]  J. Lancaster,et al.  Total Body Fat Content and Fat Topography Are Associated Differently With In Vivo Glucose Metabolism in Nonobese and Obese Nondiabetic Women , 1992, Diabetes.

[33]  M. Kondo,et al.  Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. , 1991, Kidney international.

[34]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[35]  R. Hume,et al.  Relationship between total body water and surface area in normal and obese subjects , 1971, Journal of clinical pathology.